-----BEGIN PRIVACY-ENHANCED MESSAGE----- Proc-Type: 2001,MIC-CLEAR Originator-Name: webmaster@www.sec.gov Originator-Key-Asymmetric: MFgwCgYEVQgBAQICAf8DSgAwRwJAW2sNKK9AVtBzYZmr6aGjlWyK3XmZv3dTINen TWSM7vrzLADbmYQaionwg5sDW3P6oaM5D3tdezXMm7z1T+B+twIDAQAB MIC-Info: RSA-MD5,RSA, OIpM9m/ac8D3dFbGgUSyvUuHi89Qs7eb7r4bByCYA872X6KOuXa/cpNbJe8xNonD JtHw46MUeg14NyJiYHTcXA== 0001021408-98-000532.txt : 19980810 0001021408-98-000532.hdr.sgml : 19980810 ACCESSION NUMBER: 0001021408-98-000532 CONFORMED SUBMISSION TYPE: 10-Q PUBLIC DOCUMENT COUNT: 2 CONFORMED PERIOD OF REPORT: 19980704 FILED AS OF DATE: 19980807 SROS: AMEX FILER: COMPANY DATA: COMPANY CONFORMED NAME: MOORE MEDICAL CORP CENTRAL INDEX KEY: 0000074691 STANDARD INDUSTRIAL CLASSIFICATION: WHOLESALE-DRUGS PROPRIETARIES & DRUGGISTS' SUNDRIES [5122] IRS NUMBER: 221897821 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 10-Q SEC ACT: SEC FILE NUMBER: 001-08903 FILM NUMBER: 98679723 BUSINESS ADDRESS: STREET 1: PO BOX 1500 STREET 2: 389 JOHN DOWNEY DR CITY: NEW BRITAIN STATE: CT ZIP: 06050 BUSINESS PHONE: 2038263600 MAIL ADDRESS: STREET 1: 389 JOHN DOWNEY DRIVE STREET 2: 389 JOHN DOWNEY DRIVE CITY: NEW BRITAIN STATE: CT ZIP: 06050 FORMER COMPANY: FORMER CONFORMED NAME: OPTEL CORP DATE OF NAME CHANGE: 19850611 10-Q 1 FORM 10-Q ================================================================================ SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 1998 FORM 10 - Q For the Fiscal SECOND QUARTER Ended July 4, 1998 Quarterly Report Pursuant To Section 13 or 15(d) of the Securities Exchange Act of 1934 MOORE MEDICAL CORP. (Exact name of registrant as specified in its charter) DELAWARE 1-8903 (State of incorporation) (Commission File Number) P.O. BOX 1500, NEW BRITAIN, CT 06050 22-1897821 (Address of principal executive offices) (I.R.S. Employer Identification Number) 860-826-3600 (Registrant's telephone number) SECURITIES REGISTERED PURSUANT TO SECTION 12(B) OF THE ACT: Common Stock ($.01 Par Value) American Stock Exchange (Title of Each Class) (Name of each exchange on which registered) Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding twelve months, and (2) has been subject to such filing requirements for the past 90 days. Yes X No -------- --------- 2,933,086 Number of shares of Common Stock outstanding as of August 3, 1998. Total number of pages in the numbered original is 13 This is page 1 of 13 pages. ================================================================================ MOORE MEDICAL CORP. INDEX Page No. -------- PART I. FINANCIAL INFORMATION Item 1. Financial Statements Balance Sheets at the end of the second quarter of 1998 and at the end of the year 1997....... 3 Statements of Operations for the second quarters of 1998 and 1997............................. 4 Statements of Operations for the first two quarters of 1998 and 1997......................... 5 Statements of Cash Flows for the first two quarters of 1998 and 1997......................... 6 Notes to Financial Statements.......................... 7-8 Item 2. Management's Discussion and Analysis of Results of Operations and Financial Condition............... 9-12 PART II. OTHER INFORMATION Item 4. Submission of Matters to a Vote of Security Holders.... 13 Item 6. Exhibits and Reports on Form 8-K....................... 13 Signatures..................................................... 13 2
MOORE MEDICAL CORP. Balance Sheets at end of - --------------------------------------------------------------------------------------------------- Amounts in thousands SECOND QUARTER 1998 YEAR 1997 (Unaudited) - --------------------------------------------------------------------------------------------------- ASSETS Current Assets Cash............................................... $ 438 $ 54 Accounts receivable, less allowances of $344 and $891................................ 11,025 15,212 Inventories........................................ 15,188 13,416 Prepaid expenses and other current assets.......... 2,588 2,960 Deferred income taxes.............................. 3,354 3,354 ------- ------- Total Current Assets......................... 32,593 34,996 ------- ------- NONCURRENT ASSETS Equipment and leasehold improvements, net.......... 4,437 3,511 Other assets....................................... 474 696 ------- ------- Total Noncurrent Assets...................... 4,911 4,207 ------- ------- $37,504 $39,203 ======= ======= LIABILITIES AND SHAREHOLDERS' EQUITY Current Liabilities Accounts payable................................... $ 6,351 $ 9,053 Accrued expenses................................... 7,130 5,801 ------- ------- Total Current Liabilities.................... 13,481 14,854 ------- ------- DEFERRED INCOME TAXES................................. 214 214 REVOLVING CREDIT FINANCING............................ -- 1,512 SHAREHOLDERS' EQUITY Preferred stock - no shares outstanding............ -- -- Common stock - $.01 par value; 5,000 shares authorized; 3,246 shares issued............................. 33 32 Capital in excess of par value..................... 21,667 21,644 Retained earnings.................................. 4,902 3,788 ------- ------- 26,602 25,464 Less treasury shares, at cost, 313 and 319 shares.......................................... (2,793) (2,841) ------- ------- Total Shareholders' Equity................... 23,809 22,623 ------- ------- $37,504 $39,203 ======= ======= - -------------------------------------------------------------------------------------------------
The accompanying notes are an integral part of the financial statements. 3
MOORE MEDICAL CORP. Statements of Operations for the - -------------------------------------------------------------------------------- Amounts in thousands, except per share data SECOND QUARTER ------------------------- 1998 1997 (Unaudited) - -------------------------------------------------------------------------------- Net sales................................... $30,042 $77,038 Cost of products sold....................... 20,685 65,687 ------- ------- Gross profit................................ 9,357 11,351 Selling, general & administrative expenses.. 8,250 10,413 ------- ------- Operating income............................ 1,107 938 Interest (income) expense, net.............. (18) 522 ------- ------- Income before income taxes.................. 1,125 416 Income tax provision........................ 416 150 ------- ------- Net income.................................. $ 709 $ 266 ======= ======= Basic and diluted net income per share...... $.24 $.09 ======= ======= - --------------------------------------------------------------------------------
The accompanying notes are an integral part of the financial statements. 4 MOORE MEDICAL CORP. Statements of Operations for the - --------------------------------------------------------------------------------
Amounts in thousands, except per share data FIRST TWO QUARTERS ----------------------- 1998 1997 (Unaudited) - -------------------------------------------------------------------------------- Net sales................................... $60,981 $158,080 Cost of products sold....................... 42,286 135,513 ------- -------- Gross profit................................ 18,695 22,567 Selling, general & administrative expenses.. 16,951 20,597 ------- -------- Operating income............................ 1,744 1,970 Interest (income) expense, net.............. (24) 1,039 ------- -------- Income before income taxes.................. 1,768 931 Income tax provision........................ 654 335 ------- -------- Net income.................................. $ 1,114 $ 596 ======= ======== Basic and diluted net income per share...... $.38 $.20 ======= ======== - --------------------------------------------------------------------------------
The accompanying notes are an integral part of the financial statements. 5 MOORE MEDICAL CORP. Statements of Cash Flows for the - --------------------------------------------------------------------------------
Amounts in thousands FIRST TWO QUARTERS ---------------------- 1998 1997 (Unaudited) - -------------------------------------------------------------------------------- Cash Flows From Operating Activities Net income........................................ $ 1,114 $ 596 Adjustments to reconcile net income to net cash flows provided by operating activities Depreciation and amortization.................... 613 755 Deferred income taxes............................ -- 227 Changes in operating assets and liabilities Accounts receivable............................. 4,187 (1,760) Inventories..................................... (1,772) 9,794 Other current assets............................ 372 (220) Accounts payable................................ (2,702) (5,795) Other current liabilities....................... 1,559 (617) ------- ------- Net cash flows provided by operating activities........................... 3,371 2,980 ------- ------- CASH FLOWS FROM INVESTING ACTIVITIES Equipment and leasehold improvements............ (1,539) (545) ------- ------- Net cash flows used in investing activities.. (1,539) (545) ------- ------- CASH FLOWS FROM FINANCING ACTIVITIES Revolving credit financing decrease, net........ (1,512) (2,536) Other, net...................................... 64 90 ------- ------- Net cash flows used in financing activities.. (1,448) (2,446) ------- ------- Increase (decrease) in cash........................ 384 (11) Cash at beginning of period........................ 54 16 ------- ------- CASH AT END OF PERIOD.............................. $ 438 $ 5 ======= ======= - --------------------------------------------------------------------------------
The accompanying notes are an integral part of the financial statements. 6 MOORE MEDICAL CORP. NOTES TO FINANCIAL STATEMENTS NOTE 1 - BASIS OF PRESENTATION OF FINANCIAL STATEMENTS The accompanying financial statements should be read in conjunction with the Notes to Financial Statements and Management's Discussion and Analysis of Results of Operations and Financial Condition included in the Company's 1997 Annual Report filed on Form 10-K and in this Form 10-Q Report. In the opinion of management, all adjustments necessary for a fair presentation of the results for the interim periods have been made. The results of operations for the second quarter and first two quarters are not necessarily indicative of the results to be expected for the full year. The fiscal quarters ended July 4, 1998 and June 28, 1997. NOTE 2 - BASIC AND DILUTED NET INCOME PER SHARE In the fourth quarter of 1997, the Company adopted Statement of Financial Accounting Standards No. 128, "Earnings per Share," for all periods presented. Basic earnings per share computations are determined based on the weighted average number of shares outstanding during the period which was 2,932,000 shares and 2,924,000 shares in the second quarters of 1998 and 1997, respectively, and 2,931,000 shares and 2,916,000 shares in the first two quarters of 1998 and 1997, respectively. The effect of the exercise and conversion of all securities, including stock options are included in the diluted earnings per share calculation. NOTE 3 - CONTINGENCIES Beginning in 1991, the Company entered into various supply contracts with the U.S. Department of Veterans Affairs and the Defense Department. In April 1997, the Company completed a review of its compliance with various pricing provisions of these contracts and, with the assistance of special legal counsel, concluded that adjustments may be due to the federal agencies for potential unasserted claims against the Company relating to pricing deficiencies under product supply contracts subject to General Services Administration and Department of Defense regulations. In the fourth quarter of 1996, the Company established a $3.8 million reserve for estimated pricing deficiency liabilities and associated legal costs. At the end of the second quarter of 1998, the reserve balance was $3.3 million. The final amount of the pricing deficiency adjustment is subject to the outcome of contract settlement 7 NOTE 3 - CONTINGENCIES (CONTINUED) discussions which the Company has requested with the governmental agencies or to an adjudicated disposition. In management's opinion, the ultimate resolution of this matter will not have a material adverse effect on the Company's financial position. Although management believes that the reserve is sufficient, it is possible the final resolution could exceed such reserve and could have a material impact on the statement of operations and cash flow in such period. 8 MOORE MEDICAL CORP. MANAGEMENT'S DISCUSSION AND ANALYSIS OF RESULTS OF OPERATIONS AND FINANCIAL CONDITION OVERVIEW - -------- The following table sets forth items included in the Statements of Operations as a percentage of sales for the second quarter and first two quarters of 1998 and 1997, respectively. The table also shows, for each line item, the percentage change in the 1998 periods from the comparable 1997 periods.
Second Quarter First Two Quarters ------------------------------------------ ------------------------------------------- % of Sales % % of Sales % --------------------------- ------------ --------------------------- ------------ 1998 1997 Change 1998 1997 Change ------------- ------------ ------------ ------------ ------------ ------------ Net sales......................... 100.0% 100.0% (61)% 100.0% 100.0% (61)% Cost of products sold............. 68.9 85.3 (69) 69.3 85.7 (69) ----- ----- ----- ----- Gross profit...................... 31.1 14.7 (18) 30.7 14.3 (17) Selling, general & admin. exp..... 27.4 13.5 (21) 27.8 13.0 (18) ----- ----- ----- ----- Operating income.................. 3.7 1.2 18 2.9 1.3 (11) Interest (income) expense, net.... - 0.7 (103) - 0.7 (102) ----- ----- ----- ----- Income before income taxes........ 3.7 0.5 170 2.9 0.6 90 Income tax provision.............. 1.3 0.2 178 1.1 0.2 95 ----- ----- ----- ----- Net income........................ 2.4% 0.3% 167% 1.8% 0.4% 87% ===== ===== ==== ===== ===== ====
RESULTS OF OPERATIONS - ---------------------- 1998 PERIODS COMPARED WITH 1997 PERIODS - --------------------------------------- In the fourth quarter of 1997, the Company exited from its wholesale drug distribution business to concentrate on its remaining and more profitable healthcare practitioner business. The wholesale drug distribution business generated approximately 60% of the Company's 1997 sales, while the remaining healthcare practitioner business generated approximately 40% of its sales. Sales by quarter in 1997 of the healthcare practitioner business were $24.7 million, $27.5 million, $31.4 million and $29.3 million in the first, second, third and fourth quarters, respectively. 9 SECOND QUARTER 1998 Compared with 1997 - ----------------------- Net sales of $30.0 million for the second quarter of 1998 decreased 61% from the same quarter of 1997 due to the withdrawal from the wholesale drug distribution business. Sales of pharmaceuticals decreased 87% and sales of medical/surgical supplies increased slightly. Sales of the healthcare practitioner business for the 1998 quarter were 9% higher than sales for this business in the comparable quarter of 1997. For the 1998 quarter, gross profit dollars decreased 18% to $ 9.4 million. The gross profit margin rate in the 1998 quarter increased to 31.1% of sales from 14.7% in the same quarter a year earlier. Gross profit margins are higher in the healthcare practitioner market than in the wholesale drug market. Selling, general and administrative expenses in the second quarter of 1998 decreased 21% from the quarter a year ago. The decrease is primarily attributable to reductions in staff, freight expense and other variable expenses previously associated with the wholesale drug distribution business. In the 1997 second quarter, a pre-tax charge of $580,000 was taken in connection with exiting various federal government supply contracts. The 1998 quarter benefited significantly from a $540,000 change in interest charges, due to significant positive cash flows from exiting the wholesale drug distribution business which positioned the Company with no debt and positive cash balances during the 1998 quarter. Net income for the 1998 quarter increased 167%. A decrease in gross profit was more than offset by decreases in selling, general and administrative expenses and interest expense. The decrease in expense associated with the 1997 charge related to exiting federal government supply contracts accounts for most of the increase in net income from the 1997 quarter to the 1998 quarter. Net income in the 1998 second quarter was not affected by any revenues or expenses of the former wholesale drug distribution business. FIRST TWO QUARTERS 1998 Compared with 1997 - ----------------------- Net sales for the first half of 1998 decreased 61% to $61.0 million from $158.1 million in the comparable 1997 period due to the withdrawal from the wholesale drug distribution business. Sales of pharmaceuticals decreased 87% and sales of medical/surgical supplies increased 6%. Sales of the healthcare practitioner business for the 1998 first half were 15% higher than sales for this business in the comparable period of 1997. 10 For the 1998 first half, gross profit dollars decreased 17% to $ 18.7 million. The gross profit margin rate in the 1998 half increased to 30.7% of sales from 14.3% in the same period a year earlier. Gross profit margins are higher in the healthcare practitioner market than in the wholesale drug market. Selling, general and administrative expenses during the first half of 1998 decreased 18% compared with the first half of 1997. The decrease is primarily attributable to reductions in staff, freight expense and other variable expenses previously associated with the wholesale drug distribution business. In the 1997 first half, a pre-tax charge of $800,000 was taken in connection with exiting various federal government supply contracts. The 1998 first half benefited significantly from a $1,063,000 change in interest charges, due to significant positive cash flows from exiting the wholesale drug distribution business which positioned the Company with no debt and positive cash balances during most of the 1998 first half. Net income for the first half of 1998 increased 87% as compared to the same 1997 period. A decrease in gross profit was more than offset by decreases in selling, general and administrative expenses and interest expense. The decrease in expense associated with the 1997 charge related to exiting federal government supply contracts accounts for the increase in net income from the 1997 first half. Net income in the 1998 first half was not affected by any revenues or expenses of the former wholesale drug distribution business. FINANCIAL CONDITION - ------------------- During the first half of 1998, $3.4 million in funds provided by operating activities were used to pay off the remaining bank debt of $1.5 million, for capital expenditures of $1.5 million and accounted for an increase of $0.4 million in cash. Operating activities generated cash of $4.2 million from a decrease in accounts receivable, $1.1 million from net income, $0.6 million from depreciation and amortization and $1.9 million from a net change in other assets and liabilities. Operating activities used cash of $1.8 million to increase inventories and $2.7 million for a decrease in accounts payable. The large decrease in accounts receivable was due primarily to the collection of accounts in connection with exiting from the wholesale drug distribution business. The Company's bank financing agreement provides a $10 million revolving line of credit through December, 1999. The facility provides for funding limited by a formula using accounts receivable balances and inventory levels as the primary variables. Interest on loans is charged at the prime rate or, at the option of the Company, at the Eurodollar rate plus a rate in a range of 1% to 2% depending on the financial leverage of the Company. In addition, the Company pays a 1/4% commitment fee on the unused line of credit. Substantially all assets of the Company have been pledged as collateral and the agreement contains covenants and 11 restrictions relating to asset protection, financial condition, dividends, investments, acquisitions and certain other matters. Management believes that the funding needs of the Company for operating working capital and capital expenditures will continue to be met through income from operations and financing available under its line of credit. FORWARD-LOOKING INFORMATION - --------------------------- From time to time, the Company or its representatives may have made or may make forward-looking statements, orally or in writing. Such forward-looking statements may be included in, but, not limited to, press releases, oral statements made by or with the approval of an authorized executive officer, or in this report or other filings made by the Company with the Securities and Exchange Commission. The words or phrases "trend," "expect," "grow," "will," "could," "likely result," "planned," "continued," "anticipated," "estimated," "projected" or similar expressions are intended to identify "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. The Company wishes to ensure that such statements are accompanied by meaningful cautionary statements, so as to maximize to the fullest extent possible the protections of the safe harbor established in the said Act. Accordingly, such statements are qualified in their entirety by reference to and are accompanied by the following discussion of certain important factors that could cause actual results to differ materially from such forward-looking statements. Investors should also be aware of factors that could have an impact on the Company's business or financial position or performance. These include possible: pressures on revenues resulting, for example, from customer consolidations or changes in customer buying patterns; intensified competition resulting, for example, from distributor consolidations or pricing pressures from distributors able to benefit from economies of scale or other operating efficiencies; disruptions in services on which the Company is dependent, such as by truckers in deliveries from its suppliers, by UPS or other common carriers in deliveries to its customers, by its catalog printers or in telecommunication services, or relating to its computer systems; unfavorable outcomes of litigation to which the Company may become a party; and other factors detailed from time to time in the Company's Securities and Exchange Commission filings or other readily available or generally disseminated writings. The risks identified here are not all inclusive. Reference is also made to other parts of this report that include additional information concerning factors that could adversely impact the Company's business or financial position or performance. Moreover, the Company operates in a changing and very competitive business environment. New risks may emerge from time to time, and it is not possible for management to predict all risk factors, nor can it necessarily identify or assess the impact of all such factors on the Company or the extent to which any factor or combination of factors may cause actual results to differ materially from those contained in any forward-looking statements. Accordingly, forward- looking statements should not be relied upon as a prediction of actual results. 12 PART II. OTHER INFORMATION ----------------- ITEM 4. SUBMISSION OF MATTERS TO A VOTE OF SECURITY HOLDERS --------------------------------------------------- (a) The 1998 Annual Meeting of Shareholders of the Company was held May 20, 1998. (b) At the Annual Meeting, the following persons were elected directors, with the following number of shares voted for and withheld: For Withheld --------------- ------------- Mark E. Karp 2,558,043 30,211 Steven Kotler 2,558,193 30,061 Robert H. Steele 2,558,205 30,049 Peter C. Sutro 2,558,193 30,061 Wilmer J. Thomas, Jr. 2,558,205 30,049 Dan K. Wassong 2,558,205 30,049 ITEM 6. EXHIBITS AND REPORTS ON FORM 8-K -------------------------------- (a) Exhibits -------- None. (b) Reports on Form 8-K ------------------- No report on Form 8-K was filed during the quarter. SIGNATURES ---------- Pursuant to the requirements of Section 13 or 15(d) of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized. MOORE MEDICAL CORP. (REGISTRANT) By: /s/ John A. Murray By: /s/ Susan G. D'Amato ------------------------------- ----------------------------------- John A. Murray Susan G. D'Amato Vice President - Finance and Controller and Chief Chief Financial Officer Accounting Officer August 5, 1998 August 5, 1998 13 EX-27 2 FINANCIAL DATA SCHEDULE
5 1,000 3-MOS JAN-02-1999 APR-05-1998 JUL-04-1998 438 0 11,369 344 15,188 32,593 14,646 (10,209) 37,504 13,481 0 0 0 33 23,776 37,504 30,042 30,042 20,685 20,685 8,250 0 (18) 1,125 416 709 0 0 0 709 0.24 0.24
-----END PRIVACY-ENHANCED MESSAGE-----